TY - JOUR T1 - Monitoring of L-Arginine and Endogenous Dimethylarginines in Survivor Septic Patients – A Pilot Study JF - In Vivo JO - In Vivo SP - 663 LP - 669 VL - 30 IS - 5 AU - BALÁZS NÉMETH AU - ISTVÁN KISS AU - IVÁN PÉTER AU - ZÉNÓ AJTAY AU - ÁDÁM NÉMETH AU - LÁSZLÓ MÁRK AU - ATTILA CSORBA AU - TAMÁS KŐSZEGI AU - DIÁNA MÜHL AU - PÉTER KUSTÁN Y1 - 2016/09/01 UR - http://iv.iiarjournals.org/content/30/5/663.abstract N2 - Background/Aim: Nitric oxide (NO) pathway plays a major role in the development and advancement of inflammation. We aimed to design a study and investigate its feasibility to show the changes of L-arginine, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA), which are important regulators of the NO pathway. Patients and Methods: Concentrations of L-arginine, ADMA and SDMA were measured by liquid chromatography-tandem mass spectrometry. Seventeen septic survival patients were enrolled and blood samples were obtained on the first, third and fifth day after the diagnosis of sepsis. Sixteen non-septic matched controls were recruited. Results: ADMA levels on admission correlated well with sequential organ failure assessment (SOFA) score. During the follow-up, L-arginine/ADMA ratio increased significantly from day 1 to day 3 (p=0.005), then decreased from day 3 to day 5 (p=0.023). Conclusion: This study design seems feasible to investigate changes of L-Arginine, ADMA and SDMA in sepsis survival patients. ER -